Novel antiretroviral drugs include protease (PR
5 ligand, and close down upon binding of the inhibitor or the substrate (Figure 3) . A fourstranded β sheet formed by the N-and C-termini (residues 1-5 and 95-99) of each subunit provides a series of hydrogen bonds that appear to be critical for dimerization.
As originally suggested [6] , all of the important structural elements are highly conserved, especially around the catalytic Asp residues (positions [23] [24] [25] [26] [27] [28] [29] [30] , as well as at a short region including residues 86-88 which anchor the catalytic amino acids at an appropriate conformation for catalysis. The highly conserved Arg-87, which resides on the α-helix comprising residues 87-91, forms a hydrogen bond with the side-chain of Asp-29. This interaction plays a critical role in HIV-1 PR dimerization [7] .
HIV-1 reverse transcriptase is an error-prone enzyme (reviewed in [8] ). Error rates of PR, studies on the variability of the HIV-2 PR-coding region have shown that sequence variation occurs mainly at surface positions, while the structurally important regions remain conserved [9] [10] [11] [12] [13] [14] (Figure 2 ). The degree of PR sequence conservation (< 1 % variability) in HIV-2 isolates obtained from untreated patients is around 56 %, somewhat lower than for HIV-1 PRs that shows conservation in 68 out of 99 residues [15] . In addition, there are substantial differences in the location of polymorphic sites. Thus, many of the polymorphic sites of HIV-2 PR (e.g., at positions 17, 40, 46, 68, 79 and 91) are highly conserved in the HIV-1 PR, and conversely, many of the highly polymorphic sites in the HIV-1 PR [9] are highly conserved in the HIV-2 PR (e.g., at positions 13, 37, 63, 64, 69 and 93). 4 ). Detailed analysis of the PR cleavage specificity, using oligopeptide substrates containing single-amino-acid substitutions in a substrate mimicking an HIV-1 Gag cleavage site combined with modelling studies, have revealed the importance of these residues to explain differences in substrate specificity between HIV-1 and HIV-2 PRs [17, 18] .
Clinically approved HIV-1 PR inhibitors that are also utilized in anti-HIV-2 therapy
Currently there are nine clinically approved inhibitors developed against HIV-1 PR. These drugs are saquinavir, ritonavir, indinavir, amprenavir (also licensed as fosamprenavir), nelfinavir, lopinavir, atazanavir, tipranavir and darunavir ( Figure 5 ). All of them except tipranavir, are compounds whose molecular structure mimics the structure of the PR substrates.
Interactions between the PR and those inhibitors are mainly hydrophobic, and therefore, similar to those involved in enzyme-substrate interactions. Typically, PR inhibitors contain a phenyl residue at P1 or P1´ positions. Another common feature of most PR inhibitors is that they contain a nonhydrolyzable transition-state mimic (e.g., a hydoxyethylamine group at the site corresponding to the cleavable bond in the substrates). Saquinavir was the first HIV-1 PR 7 inhibitor that was licensed for therapy. Its chemical structure resembles an HIV-1 cleavage site (see Figure 5 ), where the Pro residue at position P1´ was replaced by a saturated isoquinoline ring. Indinavir and nelfinavir also mimic the characteristic Tyr(Phe)↓Pro cleavage site.
Ritonavir was developed from a symmetric molecule, while amprenavir is a sulfonamide compound. Lopinavir was the first second-generation PR inhibitor. Its core is identical to that of ritonavir, and it was designed to diminish the interactions of the inhibitor with Val-82, a residue that is frequently mutated in HIV-1 drug-resistant strains. New, second-generation inhibitors, such as atazanavir or darunavir, have been designed to combat drug-resistant mutants mainly by increasing the number of polar interactions with main chain atoms of the PR [19] . At present, ritonavir is used only at low doses, to improve the pharmacokinetic properties of coadministered PR inhibitors.
Molecular basis of HIV-2 PR drug resistance
The molecular basis of HIV-1 drug resistance have been studied extensively. An important conclusion obtained from the analysis of crystal structures and kinetic studies with HIV PRs was that most amino acid changes that confer drug resistance in HIV-1 involve mutations at positions that contact the inhibitor but not the substrates. Therefore, resistant enzymes are capable of catalysing the cleavages required for infection but are not inhibited by the drugs [20] .
In contrast to HIV-1, very few data are available about the impact of primary or secondary PR mutations on both viral fitness and the level of drug resistance in HIV-2 infection. Nevertheless, based on the similar structure of the two enzymes, most of the knowledge obtained with HIV-1 can be utilized also in HIV-2 to predict the molecular effect of mutations observed in drug resistance.
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In addition to primary drug-resistance mutations involving residues of the HIV-1 PR ligand-binding pockets, which coincide with amino acid differences between HIV-1 and HIV-2 PRs (i.e., V32I, I47V, L76M and V82I), secondary mutations may interfere with inhibitor binding through indirect perturbations of the binding site, or by influencing the enzyme activity through changing their conformational flexibility or PR dimerization properties. The same effects are expected for HIV-2 PR. Therefore, the presence of L10I/V, G16E, K20V, L33V, E35G, M36I/V, M46I/V, Q58E, I62V, A71I/V, G73A and I93L in the HIV-2 PR sequence ( Figure 2 ) could also have an important effect on drug resistance, since the same residues are selected in the HIV-1 PR under treatment with PR inhibitors [21, 22] .
HIV-2 susceptibility to PR inhibitors in cell culture assays
Saquinavir, indinavir and ritonavir were found to be equally active against HIV-1 and the HIV-2 strains ROD and EHO, in conventional MT-4/MTT susceptibility assays [4] , although others have reported that ritonavir was less effective on HIV-2, in assays carried out with peripheral blood mononuclear cells (PBMCs) or MT-2 cells [23, 24] . On the other hand, HIV-2 ROD and EHO isolates showed IC 50 values for nelfinavir which were around 1.5 to 4 times higher than the ones obtained with reference HIV-1 strains [4, 23, 24] . The relatively weak inhibitory effect of nelfinavir (approx. 4.5-fold increase of the IC 50 for the inhibitor) on HIV-2 has been recently confirmed in assays carried out with uninfected cord blood mononuclear cells, and strains CBL-20, CBL-23 and MVP-15132 [13] . In this study, authors also showed that lopinavir was an effective inhibitor of HIV-2 strains, an observation in agreement with preliminary data reported by others [25, 26] .
Natural resistance to amprenavir has been demonstrated for several HIV-2 strains (e.g.
ROD, EHO) [4, 13, [23] [24] [25] [26] . In phenotypic assays, HIV-2 strains showed IC 50 s which were 8.8 to 9
Novel PR inhibitors, such as tipranavir, atazanavir or darunavir have been selected for their lack of cross-resistance with other PR inhibitors, but also for their higher specificity on the HIV-1 enzyme. Therefore, a loss of potency on HIV-2 strains would not be surprising.
Although, in some cases, available information is still preliminary, HIV-2 strains appear to be resistant to atazanavir [25] [26] [27] , but susceptible to darunavir [24, 26] . HIV-2 resistance to tipranavir has been reported by several groups. Published IC 50 values for this inhibitor were 2 to 9 times higher than those reported for HIV-1 strains [13, 25, 26] .
Development of resistance in cell culture
As indicated above, several amino acid residues of the wild-type HIV-2 PR are also selected under drug pressure in the HIV-1 PR [22] . However, unlike in the case of HIV-1, information regarding selection of drug-resistant HIV-2 strains in vitro is scarce. For several inhibitors, the mutational patterns involved in HIV-2 resistance are different from those observed with HIV-1.
Thus, I82L develops quickly in HIV-2 strains under tipranavir resistance [13] , while conferring high-level resistance to the inhibitor in phenotypic assays [13, 28] . Cross-resistance between tipranavir and lopinavir due to the presence of Leu-82 was observed in phenotypic assays [13] .
Unlike in the case of HIV-2, HIV-1 PR variants containing Leu-82 emerge as the result of secondary mutations in selection experiments carried out in the presence of tipranavir [29] .
The substitution of Met for Ile-54 (I54M) has been observed in HIV-2 strains selected in vitro in the presence of amprenavir, nelfinavir, and indinavir [13] . In the case of indinavir, it develops quickly, while conferring high-level resistance to amprenavir, nelfinavir and lopinavir in phenotypic assays [13, 28] . However, HIV-2 strains carrying the I54M substitution in their PR remained susceptible to saquinavir [28] . V62A/L99F combination confers high-level resistance to lopinavir and moderate resistance to nelfinavir and indinavir in phenotypic assays [13] .
Lopinavir-resistant HIV-2 variants obtained after passage of the virus in the presence of the drug (up to 1 μM) contained the V47A substitution in the viral PR, often accompanied by D17N [31] . D17N appears to have a minor effect on resistance and fitness [31] . However, the V47A mutation, which is also frequently found in lopinavir-treated patients [28, 32] , decreases lopinavir susceptibility by >10-fold in phenotypic assays [28, 31] . In contrast, V47A has a minor effect on ritonavir, nelfinavir, tipranavir and darunavir resistance. Isolates containing the V47A mutation were hypersusceptible to saquinavir [28, 31] . For other inhibitors, conflicting results have been reported. Rodés et al. [28] have shown that V47A confers amprenavir and indinavir resistance, while having no effect on atazanavir susceptibility. In contrast, Masse et al. [31] found that amprenavir and indinavir susceptibilities were not influenced by the mutation, but atazanavir susceptibility was reduced by 10-fold when V47A was introduced in the sequence background of the HIV-2 ROD strain.
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In HIV-1, I47V emerges as a major lopinavir resistance mutation [33] , since two nucleotide changes are required to obtain the I47A substitution. However, I47A has been identified in HIV-1-infected patients demonstrating evolution of lopinavir resistance, although in combination with V32I (a characteristic mutation found in the HIV-2 PR) [34] .
Sequence polymorphisms and selection of mutations in HIV-2-infected patients treated with PR inhibitors
In the HIV-1 PR, the substitution M46I has been identified as a relevant mutation in the acquisition of resistance to indinavir [35] , ritonavir [36] , nelfinavir [37] and lopinavir [34, 38] .
In the HIV-2 PR, 46I is predominant in drug-naïve individuals, where it has been found in >89
% of the isolates obtained from infected patients [10, 12, 14] . However, HIV-2 strains are susceptible to indinavir and ritonavir in vitro [4] . Although the efficacy of those drugs on HIV-2 has been poorly documented, clinical studies involving a relatively large number of patients showed that there is a significant association between the emergence of mutation I82F and ritonavir or indinavir therapy [11, 39] . Interestingly, the presence of L90M has been reported to appear in HIV-2 from patients receiving saquinavir, indinavir, ritonavir or nelfinavir, usually in combination with other relevant mutations (i.e. I54M, I54L, V71I, I82F or I84V) [9, 11, 32, 40, 41] .
In the case of nelfinavir, L90M appears to play a major role in the acquisition of resistance, as occurs with HIV-1 subtype C viruses [42] , and unlike in the case of HIV-1 subtype B, where the combination D30N/N88S mediates the acquisition of high-level resistance to the inhibitor, in the absence of previous treatments with PR inhibitors [37] .
In addition, a number of changes at positions rarely associated with HIV-1 drug resistance appear to be selected in HIV-2-infected patients treated with PR inhibitors.
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Examples are K7R, V62A and V62T, or L99F [9] . K7R appeared in patients treated with saquinavir, ritonavir or lopinavir and in those individuals, the substitution was associated with M46I but never with L90M. L99F has been found in patients failing treatment with ritonavir and nelfinavir, although in combination with S43I, K45R, I54M, V71I and A92T [43] .
Although V47A has been identified as the major lopinavir resistance mutation both in vivo and in vitro [28, 31, 32] , the presence of K45R and I64V in viral isolates from patients failing lopinavir treatment has been reported in two different studies [28, 42] . The significance of those mutations, as well as others which are found less frequently in those patients (e.g. S19P, G48A, I50V) is still uncertain.
Conclusions
The susceptibility of the HIV-2 PR to antiretroviral drugs appears to be determined by amino acid substitutions other than those contributing to antiretroviral drug resistance in HIV-1. As discussed above, sequence differences between the HIV-1 and HIV-2 PRs are expected to have a large impact on the efficiency of the antiviral treatments. While amprenavir shows poor efficiency on HIV-2, the lower activity of nelfinavir, tipranavir and atazanavir, facilitates the development of resistance to those inhibitors. Inhibitors developed as drugs targeting heavily mutated HIV-1 PRs, such as lopinavir or tipranavir, are probably less effective on the HIV-2 PR due to the different sequence background that in some cases, would facilitate the rapid development of resistance, due to the emergence of single-nucleotide mutations that confer high-level resistance to the inhibitor. Examples are V47A in the case of ritonavir-boosted lopinavir therapy [28, 31, 32] , or I82L in the case of treatment with ritonavir-boosted tipranavir [13] . In addition to the limited knowledge about how to treat and interpret results from genotypic resistance assays in HIV-2 infection, therapeutic options might be limited in the long term due to inefficacy of several PR inhibitors (i.e. poor inhibitory activity and easy 13 development of resistance). In this scenario, the design and development of novel specific drugs targeting the HIV-2 PR will gain importance, particularly with an increasing prevalence of HIV-2 infections. Our current knowledge of the interactions between the HIV-1 PR and its inhibitors should provide a solid framework for the development of specific inhibitors of the HIV-2 PR through rational design. In this context, the available crystal structures of HIV-2 PR/inhibitor complexes should be an important aid to achieve that goal. Reviewer no. 1 1) Unfortunately, limited data prevent the evaluation of all 9 approved PIs on HIV-2 both in vitro and in vivo. It would have been interesting, if the authors had focused a bit more on the effects of novel PIs, which are designed for drug resistant HIV-1 isolates and whether these may also possess activity against HIV-2 (e.g. darunavir, tipranavir).
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In addition, monitoring the infection is complicated by the lack of a commercially available assay for measurement of plasma HIV-2 viremia. Currently approved antiretroviral drugs have been designed against HIV-1 (its viral life cycle is shown in Figure 1 ), and our knowledge on the efficiency of those compounds on HIV-2, both in vivo and in vitro, is still incomplete. The mutational patterns involved in the acquisition of drug resistance in HIV-2 strains may be different from those observed in HIV-1. In some cases, the comparison of HIV-1 and HIV-2 genotypes reveals the existence of amino acid sequence differences that have been associated with drug resistance in HIV-1. These differences are responsible in part for the low accuracy of genotypic interpretation algorithms developed for HIV-1, in predicting HIV-2 drug resistance.
On the other hand, recombinant virus-based susceptibility assays use HIV-1 group M subtype B-based vectors into which patient-derived protease (PR) and/or reverse transcriptase (RT) sequences are transferred [3] .
HIV-2 shows natural resistance to the three licensed non-nucleoside RT inhibitors (i.e., nevirapine, delavirdine and efavirenz). In contrast, nucleoside RT inhibitors such as zidovudine, lamivudine, stavudine, zalcitabine and abacavir, as well as the acyclic phosphonate tenofovir retain full activity against HIV-2 strains in phenotypic assays [4] . Since the introduction of potent antiretroviral drug combination therapies, PR inhibitors have contributed to the significant reduction of morbidity and mortality due to HIV-1 infection in developed countries [5] . However, the efficacy of PR inhibitors on HIV-2 has been poorly documented.
In this review, we will discuss on the differences between the inhibitor binding site of HIV-1 and HIV-2 PRs and interactions involved in binding currently approved PR inhibitors, 4 emphasizing on the specific mutational patterns appearing in vitro and in vivo during HIV-2 infections.
Comparison of the HIV-1 and HIV-2 PRs
HIV PRs are homodimeric enzymes composed of two polypeptide chains of 99 residues. HIV-1 and HIV-2 PRs share 39-48 % identical amino acid sequences depending on the strain of virus being compared. For example, the PR of the strain HIV-1 HXB2 contains 48 amino acid residues which are conserved in the strain HIV-2 ROD (Figure 2) . The first detailed comparison of the HIV-1 and HIV-2 PR sequences and structures was made by Gustchina and Weber [6] .
A model structure of the HIV-2 PR was then generated based on the crystal structure of the HIV-1 PR complexed with an inhibitor. As of today, there are more than two hundred crystal (or NMR) structures of wild-type and mutant HIV-1 PRs deposited in the Protein Data Bank (PDB). However, the number of HIV-2 PR structures is considerably smaller (less than 30, information is available at http://www.pdb.org). Most of the HIV-2 PR structures were obtained with inhibitors that have not been used in AIDS therapy. Indinavir is the only approved inhibitor whose structure has been solved in a complex with HIV-2 PR (PDB code 1HSH) (Figure 3 ). Despite the limited information on HIV-2 PRs, it is clear that the overall topology of this enzyme is very similar to that described for the HIV-1 PR.
HIV PR homodimers contain conserved Asp residues at position 25 of each unit. These Asp residues are part of the active site, which is held in a rigid position by a network of hydrogen bonds, known as the "fireman's grip". In the absence of ligand, both PRs show perfect symmetry. Each subunit contains two layers of β sheets whose strands are oriented in an orthogonal fashion. These structures provide a hydrophobic core. In addition to the fireman's grip supporting the catalytic site, both subunits contain a flexible surface β-hairpin, known as the "flap" region (residues 42-58). These structures are flexible in the absence of the 5 ligand, and close down upon binding of the inhibitor or the substrate (Figure 3) . A fourstranded β sheet formed by the N-and C-termini (residues 1-5 and 95-99) of each subunit provides a series of hydrogen bonds that appear to be critical for dimerization.
As originally suggested [6] , all of the important structural elements are highly conserved, especially around the catalytic Asp residues (positions 23-30), as well as at a short region including residues 86-88 which anchor the catalytic amino acids at an appropriate conformation for catalysis. The highly conserved Arg-87, which resides on the α-helix comprising residues 87-91, forms a hydrogen bond with the side-chain of Asp-29. This interaction plays a critical role in HIV-1 PR dimerization [7] .
HIV-1 reverse transcriptase is an error-prone enzyme (reviewed in [8] ). Error rates of 4 ). Detailed analysis of the PR cleavage specificity, using oligopeptide substrates containing single-amino-acid substitutions in a substrate mimicking an HIV-1 Gag cleavage site combined with modelling studies, have revealed the importance of these residues to explain differences in substrate specificity between HIV-1 and HIV-2 PRs [17, 18] .
Clinically approved HIV-1 PR inhibitors that are also utilized in anti-HIV-2 therapy
Interactions between the PR and those inhibitors are mainly hydrophobic, and therefore, similar to those involved in enzyme-substrate interactions. Typically, PR inhibitors contain a phenyl residue at P1 or P1´ positions. Another common feature of most PR inhibitors is that they contain a nonhydrolyzable transition-state mimic (e.g., a hydoxyethylamine group at the site corresponding to the cleavable bond in the substrates). Saquinavir was the first HIV-1 PR 7 inhibitor that was licensed for therapy. Its chemical structure resembles an HIV-1 cleavage site (see Figure 5) , where the Pro residue at position P1´ was replaced by a saturated isoquinoline ring. Indinavir and nelfinavir also mimic the characteristic Tyr(Phe)↓Pro cleavage site.
Molecular basis of HIV-2 PR drug resistance
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HIV-2 susceptibility to PR inhibitors in cell culture assays
Saquinavir, indinavir and ritonavir were found to be equally active against HIV-1 and the HIV- [13] . In this study, authors also showed that lopinavir was an effective inhibitor of HIV-2 strains, an observation in agreement with preliminary data reported by others [25, 26] .
Development of resistance in cell culture
The substitution of Met for Ile-54 (I54M) has been observed in HIV-2 strains selected in vitro in the presence of amprenavir, nelfinavir, and indinavir [13] . In the case of indinavir, it develops quickly, while conferring high-level resistance to amprenavir, nelfinavir and lopinavir in phenotypic assays [13, 28] . However, HIV-2 strains carrying the I54M substitution in their PR remained susceptible to saquinavir [28] .
HIV-1 and HIV-2 show remarkable differences in their mutational pathways leading to nelfinavir resistance. While the emergence of D30N appears to be relevant for the acquisition of nelfinavir resistance in HIV-1 [30] , this amino acid change was not observed in selection experiments carried out with HIV-2 strains. Instead, I82F alone or I54M alone or in combination with L90M or L99F were commonly identified in nelfinavir-resistant HIV-2 strains selected in cell culture [13] V62A/L99F combination confers high-level resistance to lopinavir and moderate resistance to nelfinavir and indinavir in phenotypic assays [13] .
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Sequence polymorphisms and selection of mutations in HIV-2-infected patients treated with PR inhibitors
Conclusions
The susceptibility of the HIV-2 PR to antiretroviral drugs appears to be determined by amino acid substitutions other than those contributing to antiretroviral drug resistance in HIV-1. As discussed above, sequence differences between the HIV-1 and HIV-2 PRs are expected to have a large impact on the efficiency of the antiviral treatments. While amprenavir shows poor efficiency on HIV-2, the lower activity of nelfinavir, tipranavir and atazanavir, facilitates the development of resistance to those inhibitors. Inhibitors developed as drugs targeting heavily mutated HIV-1 PRs, such as lopinavir or tipranavir, are probably less effective on the HIV-2 PR due to the different sequence background that in some cases, would facilitate the rapid development of resistance, due to the emergence of single-nucleotide mutations that confer high-level resistance to the inhibitor. Examples are V47A in the case of ritonavir-boosted lopinavir therapy [28, 31, 32] , or I82L in the case of treatment with ritonavir-boosted tipranavir [13] . In addition to the limited knowledge about how to treat and interpret results from genotypic resistance assays in HIV-2 infection, therapeutic options might be limited in the long term due to inefficacy of several PR inhibitors (i.e. poor inhibitory activity and easy 13 development of resistance). In this scenario, the design and development of novel specific drugs targeting the HIV-2 PR will gain importance, particularly with an increasing prevalence of HIV-2 infections. Our current knowledge of the interactions between the HIV-1 PR and its inhibitors should provide a solid framework for the development of specific inhibitors of the HIV-2 PR through rational design. In this context, the available crystal structures of HIV-2 PR/inhibitor complexes should be an important aid to achieve that goal.
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